In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Coya Therapeutics, Inc. (COYA – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $4.87.
According to TipRanks, Shrader is a 3-star analyst with an average return of 0.8% and a 37.50% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Athira Pharma, Biogen, and Denali Therapeutics.
Currently, the analyst consensus on Coya Therapeutics, Inc. is a Strong Buy with an average price target of $18.00, implying a 269.61% upside from current levels. In a report released on June 7, Chardan Capital also reiterated a Buy rating on the stock with a $11.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $8.00 and a one-year low of $3.69. Currently, Coya Therapeutics, Inc. has an average volume of 125.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Read More on COYA:
